Business Context and Reporting Period
This Form 8-K, dated July 19, 2019, reports the completion of a business combination between Flex Pharma, Inc. (the "Registrant") and Salarius Pharmaceuticals, LLC ("Private Salarius"). Following the merger, the Registrant changed its name to Salarius Pharmaceuticals, Inc. and is now a clinical-stage oncology company targeting epigenetic causes of cancer. The transaction was approved by stockholders on July 12, 2019, and closed on July 19, 2019.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt figures for the combined entity at this time. Financial statements and pro forma information are scheduled to be filed within 71 days. Key capital structure details include:
- Stock Issuance: 3,045,960 shares of common stock were issued to Private Salarius unit holders.
- Post-Merger Outstanding Shares: Approximately 3,747,246 shares.
- Ownership Split: Former Private Salarius unit holders own approximately 80.1% of the combined company; former Flex Pharma stockholders own approximately 19.9%.
- Reverse Stock Split: A 1-for-25 reverse stock split was effected immediately prior to the merger.
- Trading Symbol: Changed from "FLKS" to "SLRX" on the Nasdaq Capital Market, effective July 22, 2019.
- Warrant Issuance: A warrant to purchase 42,928 shares was issued to Wedbush Securities Inc. with an exercise price of $15.17 per share.
Material Changes Versus Prior Period
The filing represents a fundamental transformation of the Registrant's business and corporate structure:
- Business Focus: Shifted from the prior operations of Flex Pharma to the clinical-stage oncology business of Private Salarius.
- Corporate Identity: Name changed from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc.
- Capitalization: Significant dilution of pre-merger Flex Pharma shareholders, who now hold a minority stake (19.9%) compared to the 80.1% held by Private Salarius stakeholders.
- Board and Management: Complete turnover of the Board of Directors and executive leadership. Prior directors and officers (including CEO William K. McVicar and CFO John McCabe) resigned. New CEO David J. Arthur and CFO Scott Jordan were appointed.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or revenue outlooks. Management commentary is limited to the description of the new business focus on epigenetic cancer treatments. Key contingencies and unusual items include:
- Delayed Financial Reporting: Required financial statements of the acquired business and pro forma combined financial information are not included in this filing and will be submitted in an amendment within 71 days.
- Stockholder Rights: Pre-merger stockholders received rights to purchase warrants exercisable six months and one day after the closing date.
- Corporate Governance Changes: New bylaws were adopted, and the 2019 Annual Meeting of Stockholders was rescheduled to October 21, 2019, with a new proposal deadline of August 1, 2019.
Important Facts for Investor Verification
- Verify the upcoming filing of Private Salarius financial statements and pro forma data within 71 days to assess the combined entity's liquidity and burn rate.
- Confirm the trading status and price of the new ticker symbol "SLRX" on the Nasdaq Capital Market.
- Review the terms of the warrant issued to Wedbush Securities Inc. and the rights issued to pre-merger stockholders for potential future dilution.
- Monitor the progress of Salarius Pharmaceuticals' clinical-stage oncology pipeline as the primary driver of future value.
- Note the new deadline for stockholder proposals (August 1, 2019) for the upcoming annual meeting.